SC
RVNC

Schubert & Co’s Revance Therapeutics, Inc. RVNC Stock Holding History

Schubert & Co’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed -$33 – 1601
2023
Q1 		$33 Hold
1
– – ﹤0.01% 1652
2022
Q4 		$18 Buy
+1
New +$23 ﹤0.01% 1630

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schubert & Co's RVNC Position: Q2 2023 in Review

Schubert & Co sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 1 share — an estimated $33 sold.

Schubert & Co first reported a position in RVNC in Q4 2022 and held it in 2 quarters. The position peaked at $33 in Q1 2023. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

  • Schubert & Co reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 1 Revance Therapeutics, Inc. share in Q2 2023, an estimated $33.
  • Schubert & Co first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 2 quarters.
  • Schubert & Co's Revance Therapeutics, Inc. position peaked at $33 in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.